Traws Pharma, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Filed herewith.
Furnished herewith.
† The XBRL related information in Exhibit 101 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | |
| Date: March 31, 2025 | | |
|---|---|---|
| | Traws Pharma, Inc. | |
| | | |
| | By: | /s/ Werner Cautreels, Ph.D. |
| | | Werner Cautreels, Ph.D.Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| | | |||
| Signature | | Title | | Date |
|---|---|---|---|---|
| | | | | |
| /s/ Werner Cautreels, Ph.D. | | Chief Executive Officer and Director(Principal Executive Officer) | | March 31, 2025 |
| Werner Cautreels, Ph.D. | | | | |
| | | | | |
| /s/ Nora Brennan | | Interim Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | | March 31, 2025 |
| Nora Brennan | | | | |
| | | | | |
| /s/ Iain Dukes, D. PHIL. | | Executive Chairman, Board of Directors | | March 31, 2025 |
| Iain Dukes, D. Phil | | | | |
| | | | | |
| /s/ Nikolay Savchuk, PH.D. | | Director | | March 31, 2025 |
| Nikolay Savchuk, Ph.D. | | | | |
| | | | | |
| /s/ Trafford Clarke, PH.D. | | Director | | March 31, 2025 |
| Trafford Clarke, Ph.D. | | | | |
| | | | | |
| /s/ Mary Teresa Shoemaker | | Director | | March 31, 2025 |
| Mary Teresa Shoemaker | | | | |
| | | | | |
| /s/ Jack E. Stover | | Director | | March 31, 2025 |
| Jack E. Stover | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | |
Index to Consolidated Financial Statements
| | Page |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 185) | F-2 |
| | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-4 |
| | |
| Consolidated Balance Sheets, December 31, 2024 and 2023 | F-5 |
| | |
| Consolidated Statements of Operations, Years ended December 31, 2024 and 2023 | F-6 |
| | |
| Consolidated Statements of Comprehensive Loss, Years ended December 31, 2024 and 2023 | F-7 |
| | |
| Consolidated Statements of Stockholders’ Equity, Years ended December 31, 2024 and 2023 | F-8 |
| | |
| Consolidated Statements of Cash Flows, Years ended December 31, 2024 and 2023 | F-9 |
| | |
| Notes to Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.